Enhancing the prediction for shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage using a machine learning approach.

Aneurysmal subarachnoid hemorrhage Machine learning approach Shunt-dependent hydrocephalus

Journal

Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181

Informations de publication

Date de publication:
19 Aug 2023
Historique:
received: 01 06 2023
accepted: 12 08 2023
revised: 31 07 2023
medline: 21 8 2023
pubmed: 19 8 2023
entrez: 18 8 2023
Statut: epublish

Résumé

Early and reliable prediction of shunt-dependent hydrocephalus (SDHC) after aneurysmal subarachnoid hemorrhage (aSAH) may decrease the duration of in-hospital stay and reduce the risk of catheter-associated meningitis. Machine learning (ML) may improve predictions of SDHC in comparison to traditional non-ML methods. ML models were trained for CHESS and SDASH and two combined individual feature sets with clinical, radiographic, and laboratory variables. Seven different algorithms were used including three types of generalized linear models (GLM) as well as a tree boosting (CatBoost) algorithm, a Naive Bayes (NB) classifier, and a multilayer perceptron (MLP) artificial neural net. The discrimination of the area under the curve (AUC) was classified (0.7 ≤ AUC < 0.8, acceptable; 0.8 ≤ AUC < 0.9, excellent; AUC ≥ 0.9, outstanding). Of the 292 patients included with aSAH, 28.8% (n = 84) developed SDHC. Non-ML-based prediction of SDHC produced an acceptable performance with AUC values of 0.77 (CHESS) and 0.78 (SDASH). Using combined feature sets with more complex variables included than those incorporated in the scores, the ML models NB and MLP reached excellent performances, with an AUC of 0.80, respectively. After adding the amount of CSF drained within the first 14 days as a late feature to ML-based prediction, excellent performances were reached in the MLP (AUC 0.81), NB (AUC 0.80), and tree boosting model (AUC 0.81). ML models may enable clinicians to reliably predict the risk of SDHC after aSAH based exclusively on admission data. Future ML models may help optimize the management of SDHC in aSAH by avoiding delays in clinical decision-making.

Identifiants

pubmed: 37596512
doi: 10.1007/s10143-023-02114-0
pii: 10.1007/s10143-023-02114-0
pmc: PMC10439049
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

206

Informations de copyright

© 2023. The Author(s).

Références

J Neurosurg. 2018 May;128(5):1273-1279
pubmed: 28598279
Nat Mach Intell. 2019 May;1(5):206-215
pubmed: 35603010
BMC Med Inform Decis Mak. 2021 Jul 20;21(1):221
pubmed: 34284756
Neurocrit Care. 2011 Sep;15(2):211-40
pubmed: 21773873
Lancet Digit Health. 2020 Jun;2(6):e279-e281
pubmed: 33328120
Neurocrit Care. 2016 Feb;24(1):104-9
pubmed: 26136147
Front Neurol. 2019 Mar 15;10:226
pubmed: 30930840
Kaohsiung J Med Sci. 1999 Mar;15(3):137-45
pubmed: 10224837
Neurosurg Rev. 2021 Oct;44(5):2837-2846
pubmed: 33474607
Neurosurgery. 2021 Jan 13;88(2):E150-E157
pubmed: 33017031
Neurosurgery. 2012 Oct;71(4):869-75
pubmed: 22801639
Nat Med. 2019 Jan;25(1):24-29
pubmed: 30617335
Nat Med. 2019 Sep;25(9):1337-1340
pubmed: 31427808
J Neurosurg. 2017 Feb;126(2):586-595
pubmed: 27035169
JAMA. 2018 Apr 3;319(13):1317-1318
pubmed: 29532063
World Neurosurg. 2016 Feb;86:226-32
pubmed: 26428322
J Cerebrovasc Endovasc Neurosurg. 2014 Jun;16(2):78-84
pubmed: 25045646
Stroke. 2019 May;50(5):1263-1265
pubmed: 30890116
J Thorac Oncol. 2009 Dec;4(12):1447-9
pubmed: 20009908
J Neurosurg. 1968 Jan;28(1):14-20
pubmed: 5635959
World Neurosurg. 2019 Jan;121:e535-e542
pubmed: 30268545
Eur J Neurol. 2016 May;23(5):912-8
pubmed: 26918845
Acta Neurochir (Wien). 2020 Dec;162(12):3093-3105
pubmed: 32642833
KDD. 2016 Aug;2016:1675-1684
pubmed: 27853627
J Hosp Med. 2016 Nov;11 Suppl 1:S18-S24
pubmed: 27805795
Neurosurgery. 2003 Apr;52(4):763-9; discussion 769-71
pubmed: 12657171
J Neurosurg. 2009 Jan;110(1):44-9
pubmed: 18950263
Front Neurol. 2022 May 27;13:737667
pubmed: 35693017
Cerebrovasc Dis. 2013;35(2):93-112
pubmed: 23406828
J Korean Neurosurg Soc. 2008 Apr;43(4):177-81
pubmed: 19096639
World Neurosurg. 2017 Oct;106:844-860.e6
pubmed: 28652120
PLoS One. 2020 Apr 6;15(4):e0231166
pubmed: 32251471
J Clin Neurosci. 2013 Aug;20(8):1134-8
pubmed: 23517672
Acta Neurochir (Wien). 2014 Nov;156(11):2059-69
pubmed: 25143185
J Neurosurg. 2021 Jul 02;136(1):134-147
pubmed: 34214980
Arch Neurol. 1989 Jul;46(7):744-52
pubmed: 2742543
Acta Neurochir (Wien). 2021 Mar;163(3):743-751
pubmed: 33389122
Neurosurgery. 2007 Nov;61(5):924-33; discussion 933-4
pubmed: 18091269

Auteurs

Dietmar Frey (D)

CLAIM - Charité Lab for AI in Medicine, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.
Department of Neurosurgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Adam Hilbert (A)

CLAIM - Charité Lab for AI in Medicine, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Anton Früh (A)

Department of Neurosurgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Vince Istvan Madai (VI)

QUEST Centre for Responsible Research, Berlin Institute for Health, Charité Unversitätsmedizin Berlin, Anna-Louisa-Karsch-Str. 2, 10178, Berlin, Germany.
School of Computing and Digital Technology, Faculty of Computing, Engineering and the Built Environment, Birmingham City University, 15 Bartholomew Row, Birmingham, B5 5JU, UK.

Tabea Kossen (T)

CLAIM - Charité Lab for AI in Medicine, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Julia Kiewitz (J)

Department of Neurosurgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Jenny Sommerfeld (J)

Department of Neurosurgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Peter Vajkoczy (P)

Department of Neurosurgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Meike Unteroberdörster (M)

Department of Neurosurgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Esra Zihni (E)

CLAIM - Charité Lab for AI in Medicine, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.
Technological University Dublin, Aungier St, Dublin, D02 HW71, Ireland.

Sophie Charlotte Brune (SC)

Department of Neurosurgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Stefan Wolf (S)

Department of Neurosurgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Nora Franziska Dengler (NF)

Department of Neurosurgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany. Nora.Dengler@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH